CLPBF
Coloplast A/S
OTC Markets OTCPKUSDEQUITY
DELAYED
Sell
-45/100
Last price
61.62
▼ 1.19 (1.89%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
62.81
Day high
65.16
Day low
65.16
Volume
3
Market cap
—
P/E (TTM)
—
52W range
56.81 – 95.43
Trailing performance
Returnvs SPY
1W
-1.89%
-3.8%
1M
-9.82%
-11.3%
3M
-0.23%
-3.6%
6M
-11.41%
-26.4%
YTD
-26.38%
-40.4%
1Y
-27.96%
-43.7%
3Y
-40.91%
-122.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on CLPBF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|
| Total revenue | $27.03B | $24.50B | $22.58B | +10.3% |
| Operating revenue | $27.03B | $24.50B | $22.58B | +10.3% |
| Cost of revenue | $8.76B | $8.17B | $7.05B | +7.2% |
| Gross profit | $18.27B | $16.33B | $15.53B | +11.9% |
| Research & development | $913.00M | $872.00M | $866.00M | +4.7% |
| Selling, general & admin | $10.07B | $8.63B | $7.80B | +16.6% |
| Total operating expense | $10.98B | $9.48B | $8.62B | +15.8% |
| Operating income | $7.29B | $6.84B | $6.91B | +6.4% |
| Net interest income | -$800.00M | -$605.00M | -$199.00M | -32.2% |
| Pre-tax income | $6.39B | $6.03B | $6.13B | +6.1% |
| Tax provision | $1.34B | $1.24B | $1.42B | +8.1% |
| Net income | $5.05B | $4.78B | $4.71B | +5.6% |
| Net income to common | $5.05B | $4.78B | $4.71B | +5.6% |
| Basic EPS | 22.46 | 22.21 | 22.14 | +1.1% |
| Diluted EPS | 22.46 | 22.20 | 22.11 | +1.2% |
| EBIT | $7.19B | $6.66B | $6.30B | +7.9% |
| EBITDA | $8.48B | $7.73B | $7.23B | +9.7% |
| Basic shares | 224.90M | 215.40M | 212.50M | +4.4% |
| Diluted shares | 224.90M | 215.50M | 212.80M | +4.4% |
| Line item | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $788.00M | $911.00M | $414.00M | -13.5% |
| Cash & short-term investments | $788.00M | $911.00M | $633.00M | -13.5% |
| Accounts receivable | $4.67B | $4.32B | $3.94B | +8.3% |
| Inventory | $3.67B | $3.52B | $3.19B | +4.3% |
| Total current assets | $10.44B | $9.94B | $8.77B | +5.1% |
| Property, plant & equipment | $6.57B | $5.98B | $5.15B | +9.9% |
| Goodwill & intangibles | $30.33B | $31.25B | $22.77B | -3.0% |
| Total assets | $48.07B | $48.16B | $37.45B | -0.2% |
| Total current liabilities | $10.20B | $16.31B | $7.34B | -37.4% |
| Current debt | $5.08B | $7.12B | $1.64B | -28.5% |
| Long-term debt | $16.56B | $11.56B | $16.36B | +43.3% |
| Total debt | $22.63B | $19.57B | $18.71B | +15.6% |
| Total liabilities | $30.13B | $30.86B | $29.15B | -2.4% |
| Retained earnings | $15.39B | $14.63B | $5.39B | +5.2% |
| Shareholder equity | $17.94B | $17.30B | $8.29B | +3.7% |
| Working capital | $240.00M | -$6.37B | $1.44B | +103.8% |
| Net tangible assets | -$12.39B | -$13.96B | -$14.47B | +11.2% |
| Shares issued | 228.20M | 228.20M | 216.00M | 0.0% |
| Line item | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|
| Net income | $7.32B | $6.77B | $6.44B | +8.1% |
| Depreciation & amortisation | $1.29B | $1.07B | $930.00M | +20.7% |
| Change in working capital | -$1.03B | -$893.00M | -$849.00M | -15.6% |
| Operating cash flow | $2.77B | $4.23B | $5.10B | -34.5% |
| Capital expenditure | -$1.35B | -$1.24B | -$1.14B | -8.5% |
| Investing cash flow | -$1.34B | -$8.96B | -$11.76B | +85.1% |
| Share buybacks | — | $0 | -$619.00M | — |
| Dividends paid | -$4.72B | -$4.25B | -$4.04B | -11.1% |
| Financing cash flow | -$1.52B | $5.26B | $6.59B | -128.8% |
| Free cash flow | $1.42B | $2.98B | $3.96B | -52.4% |
| End cash position | $788.00M | $911.00M | $414.00M | -13.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $7.36B | $7.08B | $7.04B | $6.96B | $6.93B | +3.8% |
| Operating revenue | $7.36B | $7.08B | $7.04B | $6.96B | $6.93B | +3.8% |
| Cost of revenue | $2.45B | $2.37B | $2.31B | $2.25B | $2.20B | +3.4% |
| Gross profit | $4.91B | $4.72B | $4.74B | $4.71B | $4.73B | +4.0% |
| Research & development | $281.00M | $254.00M | $247.00M | $239.00M | $239.00M | +10.6% |
| Selling, general & admin | $2.72B | $2.67B | $2.64B | $2.58B | $2.63B | +2.1% |
| Total operating expense | $2.98B | $2.90B | $2.88B | $2.79B | $2.84B | +2.8% |
| Operating income | $1.93B | $1.82B | $1.85B | $1.92B | $1.89B | +6.0% |
| Net interest income | -$37.00M | -$39.00M | -$153.00M | -$490.00M | -$316.00M | +5.1% |
| Pre-tax income | $1.87B | -$1.24B | $1.79B | $1.34B | $1.49B | +250.6% |
| Tax provision | $412.00M | -$273.00M | $394.00M | $537.00M | $579.00M | +250.9% |
| Net income | $1.46B | -$971.00M | $1.40B | $805.00M | $912.00M | +250.6% |
| Net income to common | $1.46B | -$971.00M | $1.40B | $805.00M | $912.00M | +250.6% |
| Basic EPS | 6.49 | -4.31 | 6.20 | 3.57 | 4.05 | +250.6% |
| Diluted EPS | 6.49 | -4.31 | 6.20 | 3.57 | 4.05 | +250.6% |
| EBIT | $2.08B | -$1.06B | $1.96B | $1.83B | $1.81B | +297.0% |
| EBITDA | $2.44B | $2.29B | $2.30B | $2.17B | $2.15B | +6.5% |
| Basic shares | 225.20M | 225.20M | 225.00M | 225.40M | 225.40M | 0.0% |
| Diluted shares | 225.20M | 225.20M | 225.00M | 225.40M | 225.40M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $817.00M | $1.07B | $1.13B | $726.00M | $729.00M | -23.4% |
| Cash & short-term investments | $817.00M | $1.07B | $1.13B | $726.00M | $729.00M | -23.4% |
| Accounts receivable | $4.67B | $4.59B | $4.50B | $4.79B | $4.75B | +1.7% |
| Inventory | $4.13B | $3.94B | $3.86B | $3.78B | $3.80B | +4.8% |
| Total current assets | $10.40B | $10.45B | $10.30B | $10.56B | $10.47B | -0.5% |
| Property, plant & equipment | $8.10B | $7.69B | $7.32B | $6.84B | $6.90B | +5.3% |
| Goodwill & intangibles | $27.34B | $27.48B | $30.18B | $29.92B | $31.21B | -0.5% |
| Total assets | $46.94B | $46.65B | $48.80B | $47.88B | $49.15B | +0.6% |
| Total current liabilities | $6.66B | $5.98B | $7.93B | $10.55B | $10.97B | +11.4% |
| Current debt | $2.63B | $1.97B | $3.44B | $6.68B | $6.67B | +33.1% |
| Long-term debt | $20.21B | $21.34B | $20.73B | $16.56B | $16.57B | -5.3% |
| Total debt | $23.80B | $24.23B | $25.10B | $24.21B | $24.26B | -1.8% |
| Total liabilities | $33.57B | $33.81B | $34.99B | $31.43B | $32.21B | -0.7% |
| Retained earnings | $14.43B | $12.95B | $15.03B | $16.81B | $16.29B | +11.5% |
| Shareholder equity | $13.37B | $12.84B | $13.80B | $16.45B | $16.94B | +4.1% |
| Working capital | $3.74B | $4.47B | $2.37B | $3.00M | -$500.00M | -16.5% |
| Net tangible assets | -$13.97B | -$14.63B | -$16.37B | -$13.47B | -$14.27B | +4.5% |
| Shares issued | 228.20M | 228.20M | 228.20M | 228.20M | 228.20M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.91B | -$1.21B | $1.81B | $1.83B | $1.81B | +258.6% |
| Depreciation & amortisation | $363.00M | $3.35B | $345.00M | $343.00M | $344.00M | -89.2% |
| Change in working capital | -$22.00M | -$505.00M | $182.00M | -$62.00M | -$1.09B | +95.6% |
| Operating cash flow | $1.71B | $1.47B | $2.23B | $1.63B | $742.00M | +16.6% |
| Capital expenditure | -$296.00M | -$449.00M | -$414.00M | -$418.00M | -$310.00M | +34.1% |
| Investing cash flow | -$292.00M | -$612.00M | -$412.00M | -$419.00M | -$309.00M | +52.3% |
| Dividends paid | -$1.13B | $0 | -$4.06B | -$1.13B | $0 | — |
| Financing cash flow | -$1.68B | -$934.00M | -$1.64B | -$1.18B | -$598.00M | -79.9% |
| Free cash flow | $1.41B | $1.02B | $1.82B | $1.21B | $432.00M | +39.0% |
| End cash position | $817.00M | $1.07B | $1.13B | $726.00M | $729.00M | -23.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
62.57
-1.52% from price
SMA 20
63.72
-3.29% from price
SMA 50
65.60
-6.07% from price
SMA 100
62.75
-1.81% from price
SMA 200
68.57
-10.13% from price
EMA 12
62.82
-1.91% from price
EMA 26
63.93
-3.61% from price
EMA 50
64.34
-4.23% from price
RSI (14)
19.0
Oversold
MACD (12,26,9)
-1.10
Hist -0.14
ATR (14)
0.12
0.20% of price
Realised vol 30D
26.9%
Annualised
Bollinger upper
68.39
20, 2σ
Bollinger lower
59.05
20, 2σ
50 / 200 cross
Death
65.60 vs 68.57
Trend bias
Below 200
-10.13%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.34
Less volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
26.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-40.5%
Peak to trough
Max drawdown 5Y
-68.6%
Peak to trough
ATR 14
0.12
0.20% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
GlobeNewswire · 6d ago
Coloplast A/S - Major shareholder announcement
GlobeNewswire · 6d ago
Ostomy Dressing Market Forecasts Growth from $3.80B (2026) to $4.73B by 2031, Profiling Coloplast, ConvaTec, Hollister, B. Braun & Salts Healthcare
GlobeNewswire · 14d ago
Coloplast A/S - Financial Calendar 2026/27
GlobeNewswire · 14d ago
Supporting the continued long-term and stable ownership of Coloplast
GlobeNewswire · 34d ago
Coloplast AS (CLPBF) (Q3 2026) Earnings Call Highlights: Organic Growth Steady at 6% Amid US ...
GuruFocus.com · 50d ago
Coloplast A/S - Interim Financial Report, 9M 2025/26
GlobeNewswire · 51d ago
Coloplast A/S - Interim Financial Report, 9M 2025/26
GlobeNewswire · 51d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.